ORIC:NASDAQOric Pharmaceuticals, Inc. Analysis

ORIC is trading just above its calculated support of $7.815, with the 20‑day SMA at $9.40, the 50‑day SMA at $10.32 and the 200‑day SMA at $10.88, indicating a clear bearish price structure. The RSI sits near 29, signaling oversold conditions, while the MACD histogram remains negative, reinforcing short‑term downside pressure. Volume is on an increasing trend, but the 30‑day volatility exceeds 55%, suggesting that price swings could be abrupt.
On the fundamentals side, the company holds roughly $282 million in cash against minimal debt, but it reports no revenue and sizable operating losses, resulting in a negative PE and a book‑to‑price multiple of about 2.0. Recent material news highlights the advancement of its lead candidate rinzimetostat into a Phase 3 global registrational trial in partnership with Bayer and Johnson & Johnson, which could unlock significant upside if successful. Analyst consensus is a “strong buy” with a median price target near $21, implying a potential upside of over 150% from current levels.